dual peptide FAQ

Administer the missed dose the following night and continue your regular schedule. Do not double-dose to 'catch up'. Sermorelin's mechanism depends on pulsatile GH stimulation aligned with your natural circadian rhythm. Dosing twice in one night creates a supra-physiological GH spike that can trigger negative feedback (elevated somatostatin release) and suppress your next natural pulse. Missing one dose slightly reduces weekly GH exposure but doesn't reset your protocol or negate prior progress. Consistency matters more than perfection. Five properly timed doses per week outperform seven inconsistent or mistimed doses.

Skip baseline IGF-1 measurement and you lose the only objective marker of sermorelin efficacy. IGF-1 is the hepatic product of GH signalling. It should rise 40–60% from your age-adjusted baseline within 8–12 weeks of nightly sermorelin administration. Without a pre-treatment IGF-1 level, you're dosing blind. The peptide could be degraded, improperly reconstituted, or dosed below your individual threshold, and you'd have no way to know until months of administration pass without results. Draw baseline IGF-1 before starting sermorelin, retest at 12 weeks, and adjust dose or source if the increase is less than 30%.

Discard them immediately. Cloudiness in reconstituted epithalon or sermorelin indicates protein aggregation or bacterial contamination. Either renders the peptide therapeutically useless. Aggregated proteins cannot bind to their target receptors (telomerase complex for epithalon, GHRH receptors for sermorelin), and contaminated solutions introduce endotoxins that trigger inflammatory responses unrelated to peptide activity. Properly reconstituted peptides in bacteriostatic water stored at 2–8°C remain clear and colourless for 28 days. If cloudiness appears earlier, the issue is either non-sterile reconstitution technique or temperature excursion during storage or shipping.

Slow the titration schedule or hold at the current dose for an additional week before increasing. Nausea results from GLP-1-mediated gastric emptying delay. When the stomach empties 30–40% slower, undigested food remains longer, triggering nausea receptors. This side effect is dose-dependent and typically resolves within 2–4 weeks as the body adapts. Practical mitigation strategies: eat smaller meals (200–300 calories instead of 500+), reduce dietary fat (fat delays gastric emptying further), avoid lying down within 2 hours of eating, and stay hydrated. If nausea persists beyond 4 weeks at a stable dose or involves vomiting more than twice daily, consult your research protocol supervisor. This may indicate impaired gastric motility requiring dose reduction.

Understand the receptor overlap and potential for compounding effects. Combining Adamax with other GLP-1 agonists (e.g., BPC 157 for tissue repair, MK 677 for growth hormone stimulation) doesn't create receptor competition because they act on different pathways. However, combining Adamax with another GLP-1 or GIP agonist creates redundant receptor activation and increases adverse event risk without proportional benefit. If stacking peptides, ensure each targets a distinct mechanism. For example, pairing Adamax (incretin pathway) with AOD9604 (lipolysis pathway) provides complementary metabolic effects without receptor overlap.

Discard it immediately and do not inject. Cloudiness or visible particulates indicate peptide aggregation. The protein structure has denatured and is no longer bioactive. Aggregation occurs when peptides experience temperature stress, contamination, or improper reconstitution technique (shaking instead of gentle swirling). The aggregated protein cannot bind to GLP-1 or GIP receptors and may trigger immune responses if injected. Properly reconstituted Adamax should be clear to slightly opalescent with no visible particles when held to light.

Administer the missed dose as soon as you remember, then resume your regular weekly schedule from that injection date. Because Adamax has a 5–7 day half-life, plasma levels remain therapeutic for several days beyond the scheduled dose. Missing by 3 days means you're still within the compound's effective window. Do not double-dose to compensate. This increases adverse event risk (primarily nausea and vomiting) without improving metabolic outcomes. If you miss a dose by more than 5 days, skip it entirely and resume on your next scheduled date.